1. Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab.
- Author
-
Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchanian V, Weidinger S, Mempel M, Ring J, and Ollert M
- Subjects
- Adult, Aged, Anti-Allergic Agents adverse effects, Biomarkers blood, Combined Modality Therapy, Dermatitis, Atopic blood, Dermatitis, Atopic diagnosis, Dermatitis, Atopic immunology, Disease Progression, Female, Humans, Male, Middle Aged, Omalizumab adverse effects, Pilot Projects, Remission Induction, Severity of Illness Index, Time Factors, Treatment Outcome, Anti-Allergic Agents therapeutic use, Blood Component Removal adverse effects, Dermatitis, Atopic therapy, Immunoglobulin E blood, Immunosorbent Techniques adverse effects, Omalizumab therapeutic use
- Abstract
Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.
- Published
- 2016
- Full Text
- View/download PDF